What happened: incentive disbursal under pharma PLI schemes (till March 2026)
The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, reported incentive disbursal under three PLI schemes. For the PLI Scheme for Pharmaceuticals, the performance period started in FY 2022-23, and incentives have been disbursed up to March 2026. For the PLI Scheme for Bulk Drugs and the PLI Scheme for Medical Devices, the reported disbursal figures are also stated up to March 2026.
Reported amounts disbursed since inception of the schemes (₹ in crore) till March 2026:
- PLI Scheme for Pharmaceuticals: ₹6,659 crore (performance period commenced in FY 2022-23) - PLI Scheme for Bulk Drugs: ₹87.70 crore - PLI Scheme for Medical Devices: ₹266.64 crore
Background and earlier position: performance-linked incentives and timing of sales-based release
Related current affairs
- 48 projects approved under PLI Scheme for Bulk Drugs (KSMs/DIs/APIs)
- Schemes to strengthen pharmaceutical and bulk drug manufacturing in Maharashtra
- Operational progress of Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) in Bihar (FY 2025-26)
- Schemes to promote indigenous manufacturing of high-end and high-precision medical devices (PLI, Medical Device Parks, SMDI)
- Steps to reduce import dependence: PLI schemes for pharma/medical devices, urea self-sufficiency measures, and NBS policy actions for P&K fertilizers
- Uniform Code of Pharmaceuticals Marketing Practices, 2024 to curb unethical promotion